DMPU-HF Reagent | 287966-55-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: DMPU-HF Reagent
• 英文别名: 1,3-dimethyl-1,3-diazinan-2-one;hydrofluoride
• CAS: 287966-55-6
• 化学式: C6H13FN2O
• 分子量: 148.18
• InChiKey: VJFSGFXCWXVXOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.53
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  23.6
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20190055226A1

  公开（公告）日：2019-02-21

  The present invention is directed to 5-fluoro-C-(aryl or hetercyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.

  本发明涉及5-氟-C-(芳基或杂环基)-糖苷衍生物，含有它们的药物组合物以及它们在治疗由SGLT活性调节的疾病和症状中的应用，更具体地说是双重SGLT1/2活性。
• METHODS OF HYDROFLUORINATION
  申请人：UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

  公开号：US20190176134A1

  公开（公告）日：2019-06-13

  Some embodiments of the invention include inventive catalysts (e.g., compounds of Formula (I) or (Ia)). Other embodiments include compositions comprising the inventive catalysts. Some embodiments include methods of using the inventive catalysts (e.g., in hydrofluorination of an organic compound). Further embodiments include methods for making the inventive catalysts. Additional embodiments of the invention are also discussed herein.

  本发明的一些实施例包括创新催化剂（例如，化合物的化学式（I）或（Ia））。其他实施例包括包含创新催化剂的组合物。一些实施例包括使用创新催化剂的方法（例如，在有机化合物的氢氟化反应中）。进一步的实施例包括制备创新催化剂的方法。本发明的其他实施例也在本文中讨论。
• 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US10696662B2

  公开（公告）日：2020-06-30

  The present invention is directed to 5-fluoro-C-(aryl or hetercyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.

  本发明涉及 5-氟-C-（芳基或杂环）-糖苷衍生物、含有这些衍生物的药物组合物以及它们在治疗受 SGLT 活性（尤其是双重 SGLT1/2 活性）调节的疾病和病症中的用途。
• Methods of hydrofluorination
  申请人：UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

  公开号：US10702858B2

  公开（公告）日：2020-07-07

  Some embodiments of the invention include inventive catalysts (e.g., compounds of Formula (I) or (Ia)). Other embodiments include compositions comprising the inventive catalysts. Some embodiments include methods of using the inventive catalysts (e.g., in hydrofluorination of an organic compound). Further embodiments include methods for making the inventive catalysts. Additional embodiments of the invention are also discussed herein.

  本发明的某些实施方案包括本发明催化剂（如式 (I) 或 (Ia) 的化合物）。其它实施方案包括包含本发明催化剂的组合物。一些实施方案包括使用本发明催化剂的方法（例如在有机化合物的氢氟化中）。进一步的实施方案包括制造本发明催化剂的方法。本文还讨论了本发明的其它实施例。
• 5-fluoro-c-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US11014917B2

  公开（公告）日：2021-05-25

  The present invention is directed to 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.

  本发明涉及 5-氟-C-（芳基或杂环）-糖苷衍生物、含有这些衍生物的药物组合物以及它们在治疗受 SGLT 活性（尤其是双重 SGLT1/2 活性）调节的疾病和病症中的用途。